Other

Current Income Tax Expense (Benefit)

Accenture Current Income Tax Expense (Benefit) remained flat by 0.0% to $520.16M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 12.4%, from $593.53M to $520.16M. Over 4 years (FY 2021 to FY 2025), Current Income Tax Expense (Benefit) shows an upward trend with a 5.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementCash Flow Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityModerate
First reportedQ1 2014
Last reportedQ4 2025Oct 10, 2025

How to read this metric

High current tax expense relative to net income may indicate a high effective tax rate, while low current tax expense may suggest the use of tax credits or deferred tax strategies.

Detailed definition

The amount of income taxes payable to tax authorities for the current period. This represents the actual cash tax liabil...

Peer comparison

Standard accounting metric found in the tax reconciliation section of financial statements.

Metric ID: other_current_income_tax_expense_benefit

Historical Data

5 years
 FY'21FY'22FY'23FY'24FY'25
Value$1.71B$2.42B$2.40B$2.37B$2.08B
YoY Change+41.6%-0.7%-1.3%-12.4%
Range$1.71B$2.42B
CAGR+5.0%
Avg YoY Growth+6.8%
Median YoY Growth-1.0%
Current Streak3 years decline

Frequently Asked Questions

What is Accenture's current income tax expense (benefit)?
Accenture (ACN) reported current income tax expense (benefit) of $520.16M in Q2 2025.
How has Accenture's current income tax expense (benefit) changed year-over-year?
Accenture's current income tax expense (benefit) decreased by 12.4% year-over-year, from $593.53M to $520.16M.
What is the long-term trend for Accenture's current income tax expense (benefit)?
Over 4 years (2021 to 2025), Accenture's current income tax expense (benefit) has grown at a 5.0% compound annual growth rate (CAGR), from $1.71B to $2.08B.
What does current income tax expense (benefit) mean?
The immediate cash tax liability for the current reporting period.